Through subsequent investigations into structure-activity relationships (SAR) and protein degradation mechanisms, we developed a novel and highly effective candidate, MGD-22, demonstrates potent inhibition of hematological cancer growth across a broad range of models and overcame acquired resistance to IMiDs.